Because of initial findings of cardiovascular adverse events in the initial generic sumatriptan trials and in the postmarketing surveillance studies, all trip-tans carry a drug-class warning. The use of triptans is contraindicated in patients with ischemic heart disease, Prinzmetal angina, uncontrolled high blood pressure, and prior history of cerebrovascular accident. Moreover, the concomitant use of [...]
5-HT1B/1D receptor agonists have been widely used for the treatment of moderate-to-severe migraine attacks. Sumatriptan canadian was the first triptan that was available on the market; it was followed by zolmitriptan (Zomig, As-traZeneca), naratriptan (Amerge, Glaxo Wellcome Inc), rizatriptan (Maxalt drug, Merck), and almotriptan (Axert, Pharmacia), respectively. Eletriptan (Replax, Pfizer) is pending Food and Drug [...]
Early Treatment of Migraine Attacks More recently, evidence indicates that early pharmacologic intervention during a migraine attack could provide higher levels of pain relief than later intervention. Retrospective post-hoc analysis of the Spectrum Study results was performed in patients with disabling headaches who were treated while the pain was mild. Results suggest that 50 mg [...]
Nonpharmacologic treatment modalities, such as relaxation training, thermal biofeedback combined with relaxation training, electromyographic biofeedback, and cognitive-behavioral therapy, should be considered as treatment options. The U.S. Headache Consortium recommended the aforementioned treatment modalities as Grade A. Grade B recommendations, such as behavioral therapy, were also suggested in conjunction with preventive therapy. Evidence-based treatment for migraine [...]
Pain is the most common reason for consultation with primary care physicians, and the most common pain types evaluated are back pain and headaches. Migraine headache is a common complaint, with a higher incidence reported by females. It is estimated that 6% of men and 18% of women currently suffer from this disease. However, the [...]
